Lack of efficacy of tocilizumab in acute exacerbation of pulmonary fibrosis.

IF 4.3 3区医学 Q1 RESPIRATORY SYSTEM

ERJ Open Research Pub Date : 2024-12-02 eCollection Date: 2024-11-01 DOI:10.1183/23120541.00520-2024

Giovanni Franco, Pierre Le Guen, Mathilde Le Brun, Quentin Philippot, Clairelyne Dupin, Marie-Pierre Debray, Catherine Bancal, Camille Taillé, Raphaël Borie, Bruno Crestani

引用次数: 0

Abstract

Given the high mortality rate observed in our data, tocilizumab is not recommended as a salvage therapy for patients affected by acute exacerbation of pulmonary fibrosis who did not show clinical improvement after three steroids bolus https://bit.ly/3ClggYb.

查看原文本刊更多论文

托珠单抗治疗肺纤维化急性加重缺乏疗效。

鉴于我们的数据中观察到的高死亡率，tocilizumab不推荐作为三次类固醇丸后未显示临床改善的肺纤维化急性加重患者的补救性治疗https://bit.ly/3ClggYb。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

ERJ Open Research Medicine-Pulmonary and Respiratory Medicine

CiteScore

6.20

自引率

4.30%

发文量

273

审稿时长

8 weeks

期刊介绍： ERJ Open Research is a fully open access original research journal, published online by the European Respiratory Society. The journal aims to publish high-quality work in all fields of respiratory science and medicine, covering basic science, clinical translational science and clinical medicine. The journal was created to help fulfil the ERS objective to disseminate scientific and educational material to its members and to the medical community, but also to provide researchers with an affordable open access specialty journal in which to publish their work.